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INTRODUCTION
Sleep is a multidimensional life sustaining function with 
distinct and measurable biological, behavioral, perceptual, 
and temporal attributes. Obstructive sleep apnea (OSA), the 
most common form of sleep-disordered breathing (SDB), is 
a highly prevalent disorder characterized by episodic changes 
in upper airway resistance during sleep leading to sleep 
disruption and intermittent hypoxia-reoxygenation, ultimately 
promoting increased sympathetic activity, oxidative stress, 
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ABSTRACT
Background: Chronic sleep fragmentation (SF) increases cancer aggressiveness 
in mice. Exosomes exhibit pleiotropic biological functions, including immune 
regulatory functions, antigen presentation, intracellular communication and inter-
cellular transfer of RNA and proteins. We hypothesized that SF-induced alterations 
in biosynthesis and cargo of plasma exosomes may affect tumor cell properties. 
Results: SF-derived exosomes increased tumor cell proliferation (~13%), 
migration (~2.3-fold) and extravasation (~10%) when compared to exosomes from 
SC-exposed mice. Similarly, Pre exosomes from OSA patients significantly enhanced 
proliferation and migration of human adenocarcinoma cells compared to Post. SF-
exosomal cargo revealed 3 discrete differentially expressed miRNAs, and exploration 
of potential mRNA targets in TC1 tumor cells uncovered 132 differentially expressed 
genes that encode for multiple cancer-related pathways. 
Methods: Plasma-derived exosomes from C57/B6 mice exposed to 6 wks of SF or 
sleep control (SC), and from adult human patients with obstructive sleep apnea (OSA) 
before (Pre) and after adherent treatment for 6 wks (Post) were co-cultured with 
mouse lung TC1 or human adenocarcinoma tumor cell lines, respectively. Proliferation, 
migration, invasion, endothelial barrier integrity and extravasation assays of tumor 
cells were performed. Plasma mouse exosomal miRNAs were profiled with arrays, 
and transcriptomic assessments of TC1 cells exposed to SF or SC exosomes were 
conducted to identify gene targets. 
Conclusions: Chronic SF induces alterations in exosomal miRNA cargo that 
alter the biological properties of TC1 lung tumor cells to enhance their proliferative, 
migratory and extravasation properties, and similar findings occur in OSA patients, in 
whom SF is a constitutive component of their sleep disorder. Thus, exosomes could 
participate, at least in part, in the adverse cancer outcomes observed in OSA.
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and inflammation [1, 2]. These perturbations have in turn 
been implicated in the pathophysiology of numerous end-
organ morbidities including cancer [2]. Indeed, OSA has 
been associated with increased incidence of cancer [3, 4], 
as well as with adverse effects on cancer progression and 
outcomes [5]. In this setting, murine exposures to either 
chronic intermittent hypoxia (IH) or sleep fragmentation 
(SF) mimicking components of OSA lead to increased tumor 
proliferation and invasion [6–8], possibly via alterations in 
immune function and oxidative pathways [6, 9, 10].
The bidirectional communication between cancer 
cells and their microenvironment is critical for both 
normal tissue homeostasis and tumor growth [11, 12]. 
Interactions between the tumor and its microenvironment 
(e.g., endothelial cells and stromal cells, such as fibroblasts 
or macrophages) modulate tumor cell survival and 
proliferation. It has been reported that tumor exosomes 
are important mediators of intercellular signaling within 
the tumor, by transferring mRNAs, miRNAs and proteins 
through the fusion of multi-vesicular bodies with the plasma 
membrane [13, 14]. However, exosomes are also released 
by almost every cell in response to physiological and/
or pathological signals [15], and are found in abundance 
in many biological fluids such as blood, saliva, and urine 
[16, 17], where they also mediate antigen presentation 
[18], immune responses [19, 20], cell migration [21], cell 
differentiation [22], tumor survival [23], tumor invasion 
[24], and angiogenesis. Thus, exosome cargo represents 
a potential and intriguing pathway of intercellular 
communication between tumor and host, particularly via 
delivery of miRNAs, the latter being implicated as not 
only modifiers of cancer cell malignant properties, but also 
constituting potential therapeutic targets [25–27]. 
Although both exosomes and miRNAs have recently 
become the focus of intense research, little is known about 
exosome cargo in the context of sleep disorders, such as 
OSA. We hypothesized that exosomal cargo biological 
effects on tumor cells will differ in SF-exposed mice, 
and that a restricted number of differentially expressed 
miRNAs in plasma-derived exosomal cargo from SF-
exposed mice may be present, and potentially underlie 
exosome-induced alterations in cancer cell transcriptome.
RESULTS
SF exposures promote tumor growth and 
invasion in mice
In this study, mice exposed to SF revealed the 
presence of increased tumor growth and invasiveness as 
previously described [8]. Tumor volumes were significantly 
increased in SF-exposed mice (n = 12; 2,500 ± 165 mm3) 
compared to SC-exposed animals (n = 12; 520 ± 75 mm3; 
p-value < 0.0003). Similarly, tumor weight was significantly 
higher at day 28 in SF–exposed mice (1,448 ± 260 mg) 
compared to SC (514 ± 127 mg; p-value < 0.0001). In 
addition, 73% of SF-exposed animals presented evidence 
of invasion into the surrounding muscle compared to 0% of 
those exposed to SC (p-value < 0.001). 
Exosome cell sources
We determined cell sources from plasma-derived 
exosomes obtained from SC(−) and SF(−) exposed mice in 
whom no tumors were injected (n = 12/group). As shown 
in Figure 1, increased numbers of circulating exosomes 
in SF-exposed plasma emerged when compared to SC-
exposed mice, and were derived from platelets (22,100 
± 1,618 vs.13,017 ± 1,194, p-value < 0.001), progenitor 
endothelial cells (7,308 ± 800 vs. 5,300 ± 433, p-value 
< 0.01), and monocytes (10,832 ± 1,234 vs. 7,782 ± 433, 
p-value < 0.04; Figure 1B). No differences in the number 
of exosomes originating from other leukocyte populations 
occurred between the groups.
Plasma exosomes from SF-exposed mice increase 
tumor malignant poperties in vitro
We found that both exosomes from mice exposed 
to SF without injecting TC1 cells [SF(−)] and from SF-
exposed mice injected with tumors cells [SF(+)] promoted 
increased TC1 proliferation in vitro [ vs. SC(−); p-value 
< 0.001, and vs. SC(+) p-value < 0.003; Figure 2A; 
n = 12/group). In migration assays, co-cultures of TC1 
and exosomes from SF-exposed mice increased their 
migration compared to those from SC-exposed mice, 
when fetal bovine serum was used as chemoattractant in 
the lower chamber of the Transwell system (Figure 2B; 
n = 12/group; SF(−) vs. SC(−): p-value < 0.01; SF(+) 
vs. SC(+): p-value < 0.002). However, no significant 
differences in the 3D-spheroid invasion assay were apparent 
when applying exosomes derived from SF-exposed mice 
with or without tumors when compared to the corresponding 
SC conditions (Figure 2C; n = 12; p value > 0.05). 
Plasma exosomes from OSA patients 
increase proliferation and migration of lung 
adenocarcinoma cell line
Plasma exosomes derived from untreated OSA 
patients increased in vitro lung adenocarcinoma cell 
proliferation when compared to the same patients after 
6 weeks of treatment (n = 10 subjects; Pre vs. Post: 
p-value < 0.001; Figure 3A) Similarly, increased migration 
was apparent in Pre compared to Post (n = 10; Figure 3B; 
p-value < 0.007). However, no differences were detected 
in the 3D spheroid invasion assay (n = 10; Figure 3C; 
p-value > 0.05).
SF-derived plasma exosomes induce disruption 
of endothelial cell barrier integrity
Next, to test the influence of exosomes on mouse 
endothelial bEnd3 cells, we used two different approaches: 
ECIS and immunoreactivity for occludin (ZO-1) expression. 
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Exosomes from plasma of SF-exposed mice either with 
or without TC1 tumors induced greater disruption of the 
endothelial monolayer barrier integrity compared to SC-
derived plasma exosomes (Figure 4A and 4B; p-value 
< 0.001 SF(−) vs. SC(−); p-value < 0.0001 SF(+) vs. 
SC(+)). Similar qualitative findings emerged for ZO-1 
immunohistochemical asessments (Figure 4C). 
Exosome miRNA cargo profiling
Using mouse miRNA arrays, we identified 26 unique 
miRNAs that were detectable above the background level 
among plasma-derived exosomes. As shown in Table 1, 
we found that 3 of the 26 miRNAs were significantly and 
differentialy expressed in SF-derived exosomes (2 miRNAs 
Figure 1: Plasma exosomal-cell sources in SF and SC using ImageStream MkII system. Panel (A) shows a representative 
Imagestream analysis of exosomes derived from plasma SF(−) and SC(−). Bivariate plot of each cell was identified for platelets, leukocytes, 
monocytes, endothelial and endothelial progenitor cells (EPC). Platelets were identified by expression of CD41 and absence of other 
markers, such as CD45 and CD144. Leukocytes were identified by their expression of CD45, and that population was further subgated for 
expression of CD115 to identify monocytes. Endothelial cells were identified by expression of CD144, and the EPC additionally expressed 
CD34. ImageStream data were acquired using INSPIRE and analyzed using IDEAS. Panel (B) shows the quantification for exosomes from 
each cell source in SF and SC. (n = 6 for each group).
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were up-regulated and 1 was down-regulated), and were 
further validated using qRT-PCR as shown in Table 1 (n = 8/
experimental group).
Plasma-exosomal induces differentially 
expressed mRNA in TC1 cells 
Next, we used genome-wide mRNA expression 
analysis to identify differentially expressed genes (DEG) 
by exposing TC1 cells to exosomes-derived from SF- 
and SC-exposed mice in vitro (n = 6/group). We found 
132 genes with FDR p-value < 0.05 as shown in Figure 
5. To confirm the microarray results, qRT-PCR was 
performed on selected genes (Abcf2, Ifi27l2a, Eif4g2, 
Mapk8ip3, Hoxb9, Rab37, Mthfr, Pdk1, Arhgef18, 
Mgarp, Rhot2 and Foxm1) which were randomly 
selected among the differentially expressed mRNAs in 
the arrays, and confirmed the array findings (Table 2 and 
Supplementary S3). The top 50 differentially expressed 
genes are shown in Online Supplementary Table S1.
Pathway enrichment analysis revealed that the top 5 
canonical pathways included caveolar-mediated endocytosis 
signaling (p-value < 0.005), RhoGDI signaling (p-value 
< 0.002), heme biosynthesis from uroporphyrinogen-III 
(p-value < 0.001), semaphorin signaling in neurons (p-value 
< 0.002), and pyruvate fermentation to lactate (p-value 
< 0.003). Next, to understand the functional categories of 
these DEGs on TC1 cells, we first analyzed them using 
DAVID GO enrichment analysis and KEGG pathways. The 
KEGG pathways candidates found in SF compared to SC 
are shown in Online Supplementary Table S2. 
Integrated analysis of exosomal miRNA and 
mRNA expression profiles
Integration of the 3 exosomal cargo miRNA putative 
in silico target predictions (a priori 296 theoretical genes) 
and mRNA expression profiling of exosome-treated 
TC1 cells (n = 132 genes) was performed and identified 
gene targets as follows: miR-5128 – 51 gene targets; 
miR-5112 – 178 gene targets; and miR-6366 – 67 gene 
targets, respectively; please note that there was some 
degree of overlap among the miRNA TC1 target genes). 
Supplementary Figure S1 illustrates the integration of 
miRNAs target predictions and mRNA gene expression from 
TC1 cells. To further evaluate their potential biological roles, 
we assessed the KEGG and GO databases using several 
established computational algorithms. Highly significant 
KEGG pathways and their genes are shown in Table 3. 
Five major biological processes were identified for gene 
ontology: GO:0044267~cellular protein metabolic process 
(p-value < 0.0004), GO:0043067~regulation of programmed 
cell death (p-value < 0.009), GO:0043069~negative 
regulation of programmed cell death (p-value < 0.01), 
Figure 2: Effects of plasma exosomes derived from SF(−) or SF(+) mice on mouse lung TC1 cell on proliferation, 
migration, and invasion. Compared to corresponding SC conditions, SF induces accelerated tumor cell proliferation and migration in 
TC1 tumor cells (n = 12) as shown in Panel (A) – proliferation assay, and Panel (B) – migration assay. The invasion of TC1 cells assessed 
by 3D culture panel (C) showed a trend towards increases invasion exerted by exosomes from SF(+) mice (n = 7). 
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GO:0006~protein modification process (p-value < 0.01), 
and GO:0042981~regulation of apoptosis (p-value < 0.01), 
(Supplementary Figure S2). Among the most prominent 
molecular function modules were: GO:00001~nucleotide 
binding (p-value < 0.00001), GO:0003824~catalytic 
activity (p-value < 0.016), and GO:0016301~kinase 
activity (p-value < 0.01), (Supplementary Figure S2). 
For cellular components: GO:0005737~cytoplasm, 
GO:0043229~intracellular organelle, and GO:0005~nuclear 
envelope were the most abundant (p-value < 0.01 for all), 
(Supplementary Figure S2). Using IPA software, the top 
networks that differentially associated with diseases and 
functions in SF are illustrated in Figure 6. In addition, using 
IPA software we identified a list of top networks identified in 
integrated miRNAs targets and mRNA expression including: 
cellular development, cell cycle, cellular assembly and 
organization; carbohydrate metabolism, cellular assembly 
and organization, cellular development; cell death and 
survival, tissue morphology; and cell cycle, reproductive 
system development and function, and cancer. The network 
involved in cancer is shown in Supplementary Figure S3.
We also verified the inverse correlations between the 
3 SF(−) differentially expressed plasma exosomal miRNA 
and their actual target mRNAs in treated TC1 cells (see 
Supplementary Table S3) . For example, mmu-miR-5112 
was up-regulated in plasma exosomes from SF, resulting 
in reduced expression of Arrdc3 and Fam228b.
Next, we investigated the transcriptional regulation 
of miRNAs target genes, and found that different groups 
of target genes corresponding to transcription factors 
were affected in silico in SF compared to SC as shown 
in Supplementary Table S4. Some of these putative 
transcription factors are involved in apoptosis, circadian 
rhythm, cell differentiation, and cancer. The biological 
processes of some of these targets are involved in cell 
differentation, positive regulation of cell proliferation 
and inflammatory responses. However, forkhead box M1 
(FoxM1) was the only significantly affected transcription 
factor identified as a putative mmu-miR-6366 target in 
silico that was included among the actual 132 DEGs in TC1 
cells exposed to SF(−) exosomes. 
DISCUSSION
In this study, we show that plasma-derived exosomes 
from mice exposed to chronic SF conditions that mimic the 
disrupted sleep that occurs in OSA enhance the proliferative 
and migratory properties of TC1 lung tumor cells in vitro. 
Similar assessments using exosomes from OSA patients 
before and after treatment revealed essentially identical 
findings in a human lung adenocarcinoma cell line. We 
further identified miRNA exosomal cargo differences in SF 
that consist of 3 discrete miRNAs, whereby exploration of 
their potential gene targets in TC1 tumor cells uncovered 
Figure 3: Effect of plasma exosomes from OSA patients before and after CPAP treatment on proliferation, migration, 
and invasion in a human lung adenocarcinoma cell line in vitro. Exosomes-derived from patient diagnossed with OSA before 
(Pre) and after 6 wks of adherent CPAP treatment (Post) were incubated with human lung adenocarcinoma cell line induced increased 
proliferation (Panel A), and migration (Panel B), as well as statistical trend towards increased invasion (Panel C). (n = 10 patients).
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~296 genes that encode for multiple cancer-related 
pathways. 
Emerging evidence from both animal and human 
studies have linked OSA with increased cancer incidence, 
aggressiveness, and mortality [3, 5, 7, 28, 29]. Indeed, a 
recent study indicated the presence of transcriptomic changes 
in OSA patients that pointed to cancer-related pathways 
[30]. To explore the potential implications of SF on tumor 
proliferation, we exposed mice to a SF paradigm that is non-
stressful and preserves sleep duration, whereby the in vivo 
TC1 cell murine xenograft showed remarkable acceleration 
of the tumor proliferation and local invasiveness [8], and 
the present study confirms such findings, suggesting that 
circulating exosomes and their cargo are major contributors 
to SF-induced effects. 
During the development and progression of cancer, 
the cellular composition of the tumor microenvironment is 
influenced by the activity of tumor cells which recruit and 
foster the transformation of host stromal cells into tumor 
supportive cells that actively participate in tumor progression 
[31]. Emerging evidence suggests that exosomes can interact 
with target cells in the tumor microenvironment by a number 
of mechanisms, including (1) direct stimulation of the target 
by surface-expressed ligands; (2) receptor transfer between 
the tumor cell and the target; (3) horizontal transfer of 
genetic information to the target, and (4) direct stimulation of 
the target cell by endocytic-expressed surface receptors [32, 
33]. In this context, exosomes influence tumor progression, 
metastasis, and therapeutic efficacy, and are also responsible 
for stromal activation, induction of the angiogenic switch, 
increased vascular permeability, and immune escape [34]. As 
shown in our current experiments, differences in exosome 
functions emerged between SF and SC-exposed mice, 
especially influencing TC1 cell proliferation, migration, and 
disruption of endothelial monolayer barrier. Interestingly, 
plasma derived exosomes from untreated patients with OSA 
exhibited similar in vitro effects to those of exosomes from 
SF-exposed mice when administered to a human lung non-
small cell adenocarcinoma cell line. Thus, these preliminary 
findings attest to significant changes in both the content 
and the functional properties of circulating exosomes in the 
context of OSA-induced disrupted sleep, further suggesting 
that one of the potential mechanisms underlying the adverse 
prognosis of OSA patients with solid tumors may reside in 
altered biological composition of exosomes in this disease 
[5, 28, 35].
Figure 4: Effect of plasma-derived exosomes on Electric Cell-substrate Impedance Sensing (ECIS) and confocal 
microscopy imaging. Time-course of normalized endothelial cells resistance (bEnd30 cells and their values were continuously monitored 
for up to 30 hours after adding exosomes to the confluent endothelial monolayer (Panel A). Plasma-derived exosomes from SF-exposed 
mice induce increased endothelial cell monolayer disruption compared to exosomes derived from tumor-bearing or non tumor-bearing mice 
exposed to SC (n = 8). Panel (B) shows values recorded at 30 hours (p-value < 0.001 for SF(−) vs. SC(−); p-value < 0.0001 for SF(+) vs. 
SC(+)). Panel (C) shows tight junction protein ZO-1 immunohistochemistry in bEnd3 cells following treatment with exosomes. Exosomes 
from SF and SC mice with (+) and without tumors (−) were applied to mouse bEnd3 cells for 24 hrs. Tight junction protein ZO-1 (green) 
and nuclei (DAPI blue) were immunostained with corresponding antibodies. Panel (C) is representative for SC(−), SF(−), SC(+), SF(+). 
Disruption of ZO-1 continuity is particularly apparent in SF mice with and without tumors. Images are representative of n = 6/group. Scale 
bar represents 25 µm.
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Numerous studies have identified that exosomes 
can be released from various cell types including platelets, 
cardiomyocytes, endothelial cells, stem cells and tumor cell 
lines [36]. Here, we found that the abundance of exosomes 
was increased, and that the preferentially increased 
exosomes in plasma of SF-exposed mice originated from 
platelets, progenitor cells and monocytes (Figure 1). 
Since exosomes released by cancer cells can also signal 
to stromal cells within the cancer microenvironment, and 
impact tumor cell growth, metastasis, and angiogenesis 
[37–39], we examined whether the functional properties of 
plasma derived exosomes from SF-exposed mice differed 
if the mice were tumor bearing or not. Exosomes from 
tumor-bearing mice were always associated with increased 
effects compared to plasma-derived exosomes from mice 
without tumors, suggesting either additive or synergistic 
effect between SF-altered exosomes and tumor cell-derived 
exosomes. 
Exosomes can transport and deliver a large cargo of 
proteins, lipids, and nucleic acids that in turn modify cell 
and organ function. Increasing evidence indicates that the 
effect of exosomes on target cells is mainly dependent on 
their intravesicular miRNA expression [40]. We therefore 
explored the miRNA content in exosomes using unbiased 
miRNA array approaches and identified 3 differentially-
expressed miRNAs. The gene targets of these 3 miRNAs are 
unknown based on extensive literature searches. To identify 
potential gene targets, we treated TC1 cells with plasma 
exosomes from SF- or SC-exposed mice and using whole 
genome mRNA microarrays. The most highly significant 
genes from the bioinformatics analyses on putative target 
predictions of miRNAs and mRNA expression in TC1 cells 
are Mthfr for mmu-miR-5128, Arrdc3 and Fam228b for 
mmu-miR-5112, and Arhgef18, Foxm1, Mgarp, Pdk1, and 
Rhot2 for mmu-miR-6366. For example, genetic variations 
in Mthfr gene influence the susceptibility to occlusive 
vascular disease, neural tube defects, colon cancer and 
acute leukemia, and mutations in this gene are associated 
with methylenetetrahydrofolate reductase deficiency. 
Further exploration of the differentially expressed miRNA-
Table 1: List of differentially expressed miRNAs and their validation using qRT-PCR analysis in 
plasma exosomes from SF(−) and SC(−)-exposed mice
miRNAs
Microarray qRT-PCR
Fold change P-value Fold change P-value
mmu-miR-5128 2.78 ± 0.38 0.0021 2.45 ± 0.45 0.004
mmu-miR-5112 −0.64 ±0.12 0.0039 −0.78 ± 0.14 0.001
mmu-miR-6366 1.93 ± 0.32 0.0167 1.69 ± 0.39 0.02
Figure 5: Heatmap clustering of differentially expressed genes in plasma exosomes derived from SF(−) and SC(−) 
treated with TC1 cells in vitro. The color key of the heatmap represents the different expression levels. The dendrograms show one 
dimensional hierarchical clustering of similarities and dissimilarities in expression profiles of mRNAs to better depict distinct transcriptional 
patterns among SF and SC groups. (n = 6 per group). 
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Table 2: List of differentially expressed mRNAs and their validation using qRT-PCR analysis in 
TC1 cells after treatment for 24 hours with plasma exosomes from SF- or SC-exposed mice
Gene Symbol Gene name RefSeq
Fold change
Microarray p-value qRT-PCR p-value
Adm Adrenomedullin NM_009627.1 1.76 ± 0.23 1.40E-06 1.58 ± 0.11 0.002
Ankrd37 Ankyrin repeat domain 37 NM_001039562.1 −1.51 ± 0.27 4.04E-06 −0.76 ± 0.13 0.01
HLF Hepatic leukemia factor NM_172563.3 2.45 ± 0.36 7.05E-06 4.37 ± 0.42 0.004
Mgarp Mitochondria localized glutamic acid rich protein NM_026358.3 2.12 ± 0.19 0.00003 1.72 ± 0.16 0.01
Slc7a11 Solute carrier family 7 NM_011990.2 2.63 ± 0.37 0.00002 2.18 ± 0.14 0.005
Table 3: List of integrated KEGG pathways identified from in silico putative miRNA target genes 
and actual mRNA expression in TC1 cells
Category Term Count % P-value Genes
mmu04622
RIG-I-like receptor 
signaling pathway 6 2.04 0.002
ATG5, CXCL10, MAPK12, PIN1, RELA, 
ATG12
mmu05215 Prostate cancer 6 2.04 0.007 PDGFRA, BCL2, RELA, LEF1, CDKN1A, IGF1
mmu04722
Neurotrophin signaling 
pathway 7 2.31 0.008
SHC4, PTPN11, MAPK12, BCL2, PDK1, 
RELA, RPS6KA6
mmu04920
Adipocytokine 
signaling pathway 5 1.72 0.013
PPARGC1A, PTPN11, CAMKK1, RELA, 
PRKAB2
mmu04110 Cell cycle 6 2.04 0.03 CDK7, SMC3, PLK1, SKP2, CDKN1A, TFDP2
mmu04510 Focal adhesion 7 2.31 0.05 PDGFRA, SHC4, SRC, ITGA10, BCL2, 
PPP1CB, IGF1
mmu05214 Glioma 4 1.32 0.05 PDGFRA, SHC4, CDKN1A, IGF1
Figure 6: Schematic of integrative analysis of miRNA target predictions and mRNA expression in exosome-exposed 
TC1 cells. Schema for the integrative analysis of miRNA target prediction based on miRWalk software and mRNA expression 
data derived from the treated exosomes derived from SF(−) and SC(−) in TC1 cells. Differentially expressed miRNA were used to 
identify putative gene targets and the putative mRNA targets were verified with array-based mRNA expression.
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predicted targets using the Sanger miRBase and using IPA 
software revealed that several canonical pathways that 
included Rho GDP-Dissociation Inhibitors (RhoGDIs). 
RhoGDIs are important regulators of the Rho family of 
small GTPases and the expression of RhoGDIs is altered in 
a variety of cancers in which they mediate several processes 
during tumorigenesis and cancer progression [41]. We also, 
identified 4 additional SF-modified networks, with one of 
these networks being involved in cancer biology (Figure 6).
In mammalian cells, miRNAs can direct the post-
transcriptional regulation of target mRNAs for degradation 
or translational repression via binding to the 3′UTRs 
[42, 43], and computational predictions have shown that 
miRNAs may directly regulate 10–30% of protein-coding 
genes, on average for each miRNA can regulate the 
expression of several hundred genes, [44], with each miRNA 
repressing on average 200 transcripts [45]. Both miRNAs 
and transcription factors (TFs) can exert a widespread 
impact on gene expression. For example, genome-wide 
genetic analyses in many organisms have demonstrated a 
numerous of critical roles that TFs play in controlling gene 
expression during development and in homeostasis and 
disease [46]. In our data, we found that several transcription 
factors in each of the differentially expressed miRNAs. 
For example in mmu-miR-5128, we found Cdip1 (cell 
death inducing Trp53 target 1) and this gene is involved in 
apoptosis and provides a new link between p53-mediated 
intrinsic and death receptor-mediated extrinsic apoptotic 
signaling, providing a novel target for cancer therapeutics 
aimed at maximizing the p53 apoptotic response of cancer 
cells to drug therapy [47]. For mmu-miR-5112, we found 
Elf-1 (E74-Like Factor 1) is an Ets-related transcription 
factor that is expressed at high levels in T cells and is known 
to regulate the expression of several T cell genes, including 
the granulocyte-macrophage colony stimulating factor (GM-
CSF) gene, the interleukin-2 receptor alpha subunit (IL-
2Ralpha) gene, and the CD4 gene [48]. For mmu-miR-6366, 
we found that FoxM1 (forkhead box M1) was potentially 
involved in proliferation, invasion and migration in mouse 
hepatocellular carcinoma cell lines [49]. Of note, the Foxm1 
gene is expressed in cardiomyocytes which is critical for 
proper heart development and required for cardiomyocyte 
proliferation and myocardial growth [50].
Several limitaitons to the present study deserve 
comment. First and foremost, the SF paradigm exclusively 
mimics only one of the constitutive elements of sleep 
disorders such as OSA, but does not capture the whole 
sleep disorder. Notwithstanding, the fact that periodic 
sleep disruption elicits atered exosome miRNA content and 
selectively enhances specific properties of tumor biology 
provides a strong impetus and rationale for future studies. 
Such studies will have to identify additional elements of 
exosome cargo that are affected by SF since the present 
study exclusively focused on miRNAs. Finally, the specific 
functionalities of each of the 3 miRNAs in tumor biology 
will have to be specifically investigated using miRNA 
mimics and inhibitors to uncover not only the mechanistic 
aspects of SF-induced modifications in cancer cell 
proliferation and migration, but also to develop potential 
therapeutic targets. In this context, our preliminary findings 
in patients with OSA may enable future implementation 
of this approach for designing precision in vitro reporter 
assays and interventions. 
MATERIALS AND METHODS
Animals
Eight-week onld male C57BL/6 mice (n = 48) 
were purchased from The Jackson Laboratory, housed in 
a 12 hours light/dark cycle (light on 7:00 am to 7:00 pm) 
and allowed access to food and water ad libitum. The 
experimental protocols were approved by the Institutional 
Animal Use and Care Committee, and are in close agreement 
with the NIH Guide in the Care and Use of Animals. All 
efforts were made to minimize animal suffering and to 
reduce the number of animals used.
Sleep fragmentation
The custom-designed sleep fragmentation approach 
used to induce disrupted sleep in rodents has been 
previously reported in detail [8, 51], and relies on automated 
intermittent mechanically-induced arousals of otherwise 
freely-behaving mice in a standard laboratory mouse cage, 
using a near silent motorized mechanical sweeper. This 
method does not require human contact and intervention, 
or the introduction of foreign objects and touching of the 
animals during sleep. The selected SF paradigm consisted 
in inducing arousals at 2-minute intervals between each 
sweep, implemented during the light period (7:00 a.m. to 
7:00 p.m.). Four to five mice were housed in each cage to 
prevent isolation stress.
Tumor cell lines and culture medium
TC1 cells (ATCC, Manassas, VA, USA) derived from 
primary lung epithelial cell tumors of C57/B6 mice were 
cultured at 37°C, 95% air, 5% CO
2
 incubator in full tumor 
medium as recommended by the American Type Culture 
Collection (ATCC). TC1 cells were cultured in RPMI-1640 
medium with 2 mmol/L L-glutamine adjusted to contain 
1.5 g/L sodium bicarbonate, 10 mmol/L HEPES, and 
1.0 mmol/L sodium pyruvate supplemented with 2 mmol/L 
nonessential amino acids, penicillin and streptomycin, and 
10% FBS (Life Technologies, Foster City, CA). 
Mice exposed to either control sleep conditions (SC; 
n = 12) or SF (n = 12) were inoculated with TC1 cells 
(1 × 105 cells in 0.2 mL PBS) by subcutaneous injection into 
the right lower flank. Tumors volumes were estimated every 
3 days by externally measuring its length and width with 
an electronic caliper. After 28 days from tumor injection 
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during which the sleep-related exposures were continued, 
mice were sacrificed, blood collected, and tumors excised 
and weighed. 
The human adenocarcinoma, non-small cell lung 
cancer cell line was obtained from ATCC (CRL-5800, 
ATCC, Manassas, VA) and used for experiments with 
OSA patients-derived plasma exosomes (see below). 
Plasma collection and exosome isolation
Peripheral blood samples were drawn from each 
mouse and collected in vacutainer tubes containing 
EDTA (Becton Dickinson, Franklin Lakes, NJ). Blood 
samples were centrifuged at 2000 × g for 20 min at 4°C, 
and the supernatant transferred into microcentrifuge 
tubes and aliquoted and stored at −80°C. Exosome were 
isolated from frozen plasma using the Total Exosome 
Isolation Kit according to the manufacture’s protocol (Life 
Technologies, Grand Island, NY). Briefly, plasma samples 
were centrifuged at 2000 × g for 20 minutes to remove cell/
debris. The supernatants were precipitated by 0.2 volume 
of the Total Exosome Isolation Reagent (volume/volume). 
The mixtures were then incubated at 4°C for 45 minutes 
followed by centrifugation at 10,000 × g for 5 minutes. The 
supernatants were aspirated and discarded, and the exosome 
pellets were re-suspended in 1× PBS buffer and then stored 
at −80°C until used. Exosome size was determined using 
electron microscopy as previously described [52]. 
Exosome-cell sources
Isolated exosomes from SC and SF-exposed mice 
were subjected to ImageStream imaging cytometry 
for detection of their cell sources. Briefly, 100 mL 
of exosomes were stained with appropriately titrated 
antibodies (BioLegend, San Diego, CA) as follows: 
CD144-PE (1:20), CD34-APC (1:20), CD41-Alexa 488 
(1:20), CD115-BV421 (1:20), CD45-BV605 (1:20). First, 
exosomes were incubated with 5mL Fc blocking reagent 
(TruStain FcX - BioLegend) at room temperature (RT) 
for 10 minutes. An antibody cocktail of all 5 antibodies 
was created and queued up to 100 µl per sample by 
adding 75 mL per sample of Brilliant Stain Buffer (BD 
Biosciences, San Jose, CA). The diluted antibody cocktail 
was passed through a 0.1 µm filter, and 100 mL of blocked 
sample was added and incubated for 60 minutes at 4°C. 
Stained exosomes were pelleted using 17,000 × g force 
for 10 minutes. The pellet was suspended in exactly 100 
mL of filtered wash buffer (final volume) and transferred 
to a sterile 96 well, U-bottom microtiter plate and loaded 
onto the ImageStreamX MkII (ISXMkII) image cytometer 
(Millipore/Amnis, Seattle, WA). The ISXMkII was set 
to collect fluorescence from all 5 markers as well as 
Brightfield (BF) and Side Scatter light (SS) using the 60X 
objective. Fluorescent Size Standard Kits with sizing beads 
(20 nm, 100 nm, 500 nm and 1000 nm) were obtained from 
Spherotech (Spherotech Inc. Lake Forest, IL) and used for 
calibration. Excitation of the various fluorophores was 
performed by the 4 high-powered lasers on the system, 
specifically, 90 mW 405 nm, 100 mW 488 nm, 200 mW 
561 nm, and 120 mW 640 nm laser. 50,000 events were 
collected for each sample, when possible. Compensation 
was done using VersaComp beads (Beckman Coulter, 
Miami, FL) stained with the same antibodies used in the 
assay. Five hundred beads of each color were collected, 
and an auto-compensation was done using the IDEAS 
6.0 data analysis software. Each gated population was 
interrogated via the image gallery to determine the upper 
and lower limits of exosomes size and shape. Using the 
IDEAS program, submicron sized events were gated based 
on BF area and Low SS intensity. Since the ISXMkII is 
a syringe-based, volumetric system, absolute counts (in 
objects/mL) are automatically calculated as part of the 
region statistics. These values were tabulated for each of 
the populations in each sample.
Cell culture and ECIS
bEnd3 cells (ATCC, Manassas, VA, USA), an 
immortalized murine endothelial cell line derived from 
primary murine brain microvasculature transformed by 
polyomavirus middle T antigen was purchased from 
American Type Culture Collection (ATCC, Manassas, VA, 
USA). Cells were grown in Dulbecco’s modified Eagle’s 
medium supplemented with 4.5 g/L glucose, 3.7 g/L sodium 
bicarbonate, 4 mmol/L glutamine, 10% fetal bovine serum, 
100 U/mL penicillin, and 100 mg/mL streptomycin, pH 
7.4, and they were incubated at 37°C and 5% CO
2
 in cell 
culture incubator. For continuous passaging, the cells were 
trypsinized and centrifuged at 150 × g for 7 min, and re-
plated at appropriate densities. 
For Electric Cell-substrate Impedance Sensing (ECIS), 
bEnd3 cells were grown in DMEM media containing 
2% FBS for 24 hrs. Cells were seeded (30,000 cells) and 
grown to confluence into ECIS arrays (8W10E, Applied 
Biophysics, Troy, NY) as a single confluent monolayer. 
ECIS monitors the impedance of small 250-µm diameter 
gold film electrodes used as substrates for cell growth. The 
next day, plasma-derived exosomes from a single mouse 
corresponding to each of the 4 conditions (SC-no tumor 
(SC(−), SC with tumor (SC(+), SF-no tumor (SF(−), and 
SF with tumor (SF(+)) were added to the ECIS for 30–40 
hours, and the capacitance of the monolayer was monitored 
continuously at high frequency (40 kHz) and the resistance 
at a low frequency (400 Hz). Experiments for each condition 
were always conducted in duplicate wells.
Immunofluorescent staining
Confluent monolayers of bEnd3 were grown on 
cover slips in 12-well plates for 24 hrs. with DMEM media 
containing 10% FBS. Following 24 hours, cells were washed 
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with DMEM media containing 2% FBS, and maintained in 
the same media. Exosomes were added to cover slips for 
24 hrs. Cells were fixed with 4% (w/v) paraformaldehyde 
in PBS for 20 min at room temperature (RT), and the cell 
membranes were permeabilized by incubation with 0.25% 
(v/v) Triton-X-100 in PBS for 10 min. After washing with 
PBS the samples were blocked with 3% (w/v) bovine 
serum albumin in PBS for 45 min at room temperature. 
Cells were followed by overnight incubation at 4oC with 
zonula occludens (ZO-1) rabbit polyclonal antibodies (1:500 
Life technologies, Grand Island, NY). After a brief wash 
in PBS, cells were incubated with Alexa 488 anti-rabbit 
secondary antibodies (1:1000, 2 mg/ml; Life Technologies, 
Grand Island, NY) for 1 hour. Images were captured with 
a Leica SP5 Tandem Scanner Spectral 2-photon confocal 
microscope (Leica Microsystems, Inc., Buffalo Grove, IL) 
with a 63 × oil-immersion lens. 
Human subjects 
To examine whether exosome effects induced by SF 
exposures cwould be replicated in humans suffering from a 
slepe disorder associated with substantial sleep disruption, 
we obtained plasma samples from 10 patients diagnosed 
with obstructive sleep apnea (OSA) using overnight in-
laboratory polysomnography. The mean age was 52.5 ± 6.7 
years, 7 were males, body mass index was 34.7 ± 4.2 kg/m2, 
and their apnea-hypopnea index, a measure of OSA severity, 
was 36.7 ± 8.3 events per hour of sleep (i.e., moderate to 
severe OSA), with arousal index being 24.8 ± 7.3/hour of 
sleep. All the participants provided written informed consent 
and the research protocol was approved by the research 
ethical board at the University of Chicago (protocol # 10-
702-A-CR004). For each patient, blood was collected 
before starting continuous positive airway pressure (CPAP) 
treatment (Pre), as well as following 6 weeks of adherent 
CPAP treatment (Post). Adherence to CPAP treatment was 
defined as using the device at least 6 nights per week for 
> 5 hours per night. Polysomnographic findings during 
CPAP showed AHI of 2.7 ± 1.0 events per hour of sleep 
(p < 0.001 vs. Pre) with arousal index decreasing to 10.3 ± 
3.8/hour of sleep (p < 0.001 vs. Pre). Plasma was isolated 
from peripheral blood samples using centrifugation at 2000 × 
g for 20 min at 4°C and stored at −80°C until further analysis.
Proliferation assay
TC1 cells (2.5 × 104) were cultured in 6-well plates and 
exosomes were added to the cells. Cultures were maintained 
in TC1 complete growth medium (without G418) at 37°C 
and 5% CO
2
 for 48 hrs. At the end, cells were harvested, 
labeled with CD45 and counted by flow cytometry. For 
human lung adenocarcinoma cell line, cells (2 × 104) were 
grown for 72 hrs in RPMI-1640 medium modified to contain 
2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 
4500 mg/L glucose, and 1500 mg/L sodium bicarbonate 
containing 10% FBS, for use in incubators using 5% CO
2
 in 
air at 37°C. Exosomes from either Pre- or Post-treatment 
were added to the cells every 24 hrs for 72 hrs. 
Migration test
Migration assays were performed using mouse lung 
TC1 cells or human lung adenocarcinoma cells in 24-well-
transwell inserts with 8 μm pore size (3422, Corning, 
NY). TC1 cells (5 × 104) were cultured on top in serum 
free medium either in single culture or with and without 
exosomes isolated from either SC or SF. Human cancer cells 
(2 × 104) were cultured also in the top in serum free medium 
either in single culture, with and without exosomes isolated 
from Pre or Post conditions. The cells cells were allowed 
to migrate for 18 hours for TC1 and 40 hours for human 
cells from the starved medium to the lower compartment 
by using 10% FBS as chemoattractant. The cells were 
harvested after 18 hours from the bottom surface, stained 
with CD45 antibody, and counted by flow cytometry.
Three-dimentional spheroid invasion test
Invasion assays were performed using TC1 cells 
(3 × 103) or human lung adenocarcinoma cells (2 × 103). 
Cells were seeded with exosomes and the invasion test 
was monitored for 6 days, using a commercially available 
3D spheroid cell invasion assay (3500-096-K, Trevigen, 
Gaithersburg, MD). Appropriate controls included samples 
without invasion matrix. The 3D cultures were visualized 
by an Axiovert 200 M fluorescence microscope (Zeiss, 
Oberkochen, Germany), and phase contrast images of the 
spheroids were obtained at 4× magnification. SlideBook 
5.5 software (Intelligent Imaging Innovations, Denver, 
CO, USA) was used to measure the radius of the invasive 
structures to determine the extent of 3D by a blinded 
investigator. The area of invasion was determined as the 
area of the spheroid embedded in the invasion matrix minus 
its corresponding control without invasion matrix.
Total RNA and miRNAs isolations
Total RNA was isolated from TC1 cells treated 
with exosomes isolated from mice exposed to SC(−) 
(n = 6) or SF(−) (n = 6) using miRNeasy Mini kit (Qiagen, 
Turnberry Lane, Valencia, CA). Total RNA containing 
miRNAs were isolated from plasma exosomes SC(−) and 
SF(−) using the miRNeasy Serum/Plasma Kit according 
to the manufacturer’s instructions (Qiagen, Turnberry 
Lane, Valencia, CA). The RNA quality and integrity were 
determined using the Eukaryote Total RNA Nano 6000 
LabChip assay (Agilent Technologies) on the Agilent 2100 
Bioanalyzer. The quality of miRNA was determined using 
Agilent Small RNA Kit according to the manufacturer’s 
protocol. Both total RNA and miRNA samples were 
quantified on a Nanodrop 2000 (Ambion, Austin, TX). 
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Exosomal miRNAs microarrays profiling 
Total RNA containing miRNAs (100 ηg) from a 
total of 16 plasma exosome samples (SC(−): n = 8 and 
SF(−): n = 8) were reverse transcribed. Each sample was 
prepared according to the Agilent’s miRNA recommended 
approach using the one-color technique. miRNA was 
dephosphorylated with calf intestine alkaline phosphatase 
(GE Healthcare Europe GmbH), denatured with dimethyl 
sulfoxide, and labeled with pCp-Cy3 using T4 RNA ligase 
(GE Healthcare Europe GmbH). The labeled miRNAs 
were hybridized to custom 8 × 60 K mouse microarrays, 
consisting of 60-mer DNA probes synthesized in situ 
that represent 2006 miRNA (Version 19.0) and each 
of them represented by 40 features probes (Agilent), 
Santa Clara, CA). After hybridization and washing, the 
arrays were scanned with an Agilent microarray scanner 
using high dynamic range settings as specified by the 
manufacturer. Microarray results were extracted using 
Agilent Feature Extraction software (v12.0). Bioconductor 
package AgiMicroRna [53] was used to perform the 
data preprocessing and limma [54] was also used for the 
differential expression analysis. The p-values were corrected 
for multiple testing by false discovery rate (FDR) using 
Benjamini-Hochberg procedure [55]. 
Target gene predictions and analysis
Gene targets for differentially expressed miRNAs 
were initially computationally examined for miRNA target-
prediction programs using miRwalk (http://zmf.umm.
uni-heidelberg.de/apps/zmf/mirwalk2/) with 12 predicted 
target softwares (miRWalk, Microt4, miRanda, mirbridge, 
miRDB, MiRMap, miRNAMap, Pictar2, PITA, RNA22, 
RNAhybrid, and Targetscc). In order to improve the 
reliability of the miRNA targets, only target genes predicted 
by at least 5 of the programs were selected. The Gene 
Ontology (GO) terms and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways of target genes were analyzed 
using the online DAVID program (http://david.abcc.ncifcrf.
gov/). The web-based computational tool DIANA-mirPath 
v2.1 [56] was used to predict the target genes and altered 
pathways among differentially expressed miRNAs.
mRNA microarrays for assessment of exosome 
targets in TC1 cells
Total RNAs were isolated from TC1 cells treated with 
exosomes from SC(−) (n = 6) and SF (−) (n = 6). Briefly, 
purified total RNAs were processed for labeling using the 
Low RNA Input Fluorescent Linear Amplification Kit 
(Agilent Technologies, Santa Clara, CA) and hybridized 
with whole-genome mouse Agilent microarrays (8 × 60 K). 
Equal quantities of total RNA (25 ηg) for each sample 
were labeled, and the quality of each cRNA sample was 
evaluated using 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA). Each sample was hybridized to an Agilent 
oligonucleotide microarray for all of the 12 independent 
experiments. The microarray slides were scanned using 
Agilent dual-laser Microarray Scanner and the digitized 
images were acquired and processed using Agilent Feature 
Extraction (FE) software v.12.0. The background corrected 
data were normalized between arrays using cyclic Loess 
method [57].
We applied limma moderated t-test to detect 
differentially expressed genes, considering the batch effect 
caused by different chips as covariates in the linear model. 
P-values were adjusted by Benjamini-Hochberg method 
[55]. The differentially expressed data were analyzed using 
Ingenuity Pathway Analysis (IPA) software (Ingenuity 
Systems, Redwood City, CA) to perform functional 
classifications comparing SC and SF conditions. Pathway 
analysis and Gene Ontology (GO) analysis were performed 
to reveal the biological functions of differentially expressed 
genes.
Integrated analysis of miRNA and mRNA 
expression profiles
Integrated analysis of the miRNA putative targets and 
mRNA expression profiles derived from TC1 treatments 
were carried out using the differentially expressed miRNAs 
and mRNAs. The predicted mRNAs were initially 
computationally predicted by miRNA target-prediction 
programs using miRwalk (http://zmf.umm.uni-heidelberg.
de/apps/zmf/mirwalk2/) as described above. We used the 
negative regulation relationship between the miRNAs 
and mRNAs to associate the differentially expressed 
miRNAs and mRNA expression data, using FDR, p < 0.05 
and fold-change 1.5. The Agilent identifiers of the FDR 
significant probes were uploaded and mapped to genes in 
the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) for functional annotation. Also, the 
data were uploaded into Ingenuity software (Qiagen). 
For the transcription factors in the miRNA-mRNA 
interaction network, we used AnimalTFDB (www. 
bioguo.org/AnimalTFDB/download_index.php?spe=Mus 
%20musculus). These transcription factors were annotated 
in the miRNA-mRNA interaction networks using mygene 
(http://mygene.info; [58]).
Validation of miRNA and mRNA expression
Quantitative real-time polymerase chain reactions 
(qRT-PCR) were utilized for assessment of mRNA and 
miRNA expression using the ABI PRISM 7500 System 
(Applied Biosystems, Foster City, CA). Total RNAs 
were validated using SYBR Green Master Mixes (life 
technology) according to the manufacturer’s instructions. 
Primers for gene of interest were designed using Primer 
3 software (http://bioinfo.ut.ee/primer3-0.4.0/), and 
each primer made was synthesized by Integrated DNA 
Technologies (IDT, Coralville, IA). Total RNA of 500 ηg 
was reverse transcripted into cDNA using a High-Capacity 
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cDNA Archive Kit (Applied Biosystems, Foster City, 
CA). Expression levels of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used for normalization 
levels. All experiments were performed in triplicates. The 
cycle number (Ct) values were averaged and the differences 
between the housekeeping gene Ct and the gene of interest 
Ct were calculated to measure the relative expression of the 
gene of interest using the 2−ΔCT method [59]. The results are 
presented as fold change (SF relative to SC conditions). 
For miRNAs, selected miRNAs were reverse 
transcribed with looped miRNA-specific reverse 
transcriptase (RT) primers (Applied Biosystems, Foster City, 
CA) using the TaqMan microRNA mouse assay according 
to the manufacturer’s protocol. Briefly, RT reactions 
were performed in a volume of 15 µl, and each reaction 
contained 10 ηg of enrich miRNA. RT reactions were 
performed on a 7500 (Applied Biosystems, Foster City, 
CA). Reactions without addition of reverse transcriptase 
were performed alongside cDNA synthesis of each sample 
and used in subsequent procedures to control for potential 
genomic DNA contamination. All TaqMan assays were run 
in triplicate using TaqMan Universal PCR Master Mix II 
without UNG (Applied Biosystems, Foster City, CA). The 
qPCR results were normalized against an internal control 
(RNU6), and then expressed as fold changes.
Statistical methods
For tumor malignancy related variables measured 
in vitro, 2-Way ANOVA were conducted with treatment 
(SC vs. SF) followed by post-hoc tests. Differences were 
determined by Student t tests or ANOVA with 2-tailed 
p < 0.05 accepted as statistically significant. Data are 
presented as mean ± SD. Statistical analyses were 
conducted using SPSS 21.0 software for Windows (IBM, 
Armonk, NY).
CONCLUSIONS
The present study confirmed our previous findings 
that SF increases tumor proliferation, migration and 
invasion in vivo. More importantly, we found that 
circulating plasma exosomes obtained from either 
sleep fragmented mice or OSA patients enhance tumor 
cell line proliferation and migration in vitro indicating 
that these exosomes may serve as vehicles of cell–cell 
communication that underlie adverse cancer prognosis in 
the context of perturbed sleep. We also identified a unique 
set of exosomal miRNAs in SF-exposed mice that further 
raise the possibility that tumor cells and surrounding stroma 
may be altered via transfer of exosomal miRNAs. There 
is no doubt that improved understanding of the complex 
network of genes and cellular signaling transduction 
pathways regulated by exosomal miRNAs in the context of 
SF will augment our knowledge on the potential effects of 
OSA in cancer patients.
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